Is AOD-9604 Legal in Washington State?

What AOD-9604 Actually Is

AOD-9604 is a synthetic peptide corresponding to amino-acid residues 176 through 191 of human growth hormone (hGH), with a tyrosine added at the N-terminus. Researchers originally studied it as a lipolytic agent, meaning it was designed to stimulate fat breakdown without the insulin-resistance or IGF-1-mediated growth effects associated with full-length hGH. The compound was developed by Metabolic Pharmaceuticals, which ran it through clinical trials for obesity under the brand name Tyr-hGH Frag 176-191.

Mechanism of Action

AOD-9604 binds to beta-3 adrenergic receptors in adipose tissue and may stimulate lipolysis through a pathway distinct from the growth-hormone receptor. Unlike full-length hGH, it does not appear to stimulate IGF-1 production at the doses studied clinically, which is why researchers considered it a potentially safer weight-loss candidate [1].

Clinical Trial History

Metabolic Pharmaceuticals completed multiple Phase 2 trials in the early 2000s. A 12-week randomized controlled trial (N=300) published data suggesting modest reductions in body fat at 1 mg oral doses, though the effect size did not meet the threshold Metabolic Pharmaceuticals needed to justify Phase 3 investment [2]. The company discontinued further development, and no Phase 3 data exist. The FDA never received a New Drug Application (NDA) for AOD-9604, which means the compound has never been approved as a finished drug for any indication [3].

Federal Legal Framework Governing AOD-9604

AOD-9604 is not a controlled substance under the Controlled Substances Act (CSA). That matters because it means simple possession is not a federal crime in the way possession of a Schedule III anabolic steroid would be [4]. The harder regulatory question involves whether a compounding pharmacy can legally prepare and dispense it.

FDA Drug Approval Status

The FDA's drug approval database (Drugs@FDA) contains no approved NDA or ANDA for AOD-9604 in any dosage form [3]. Under 21 U.S.C. 321(g), a substance intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans meets the definition of a drug regardless of whether it is approved. Compounding pharmacies that prepare AOD-9604 are therefore compounding an unapproved drug, which the FDA tolerates only within specific statutory frameworks.

503A Compounding (Traditional Pharmacies)

Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) permits traditional compounding pharmacies to prepare drugs without FDA approval, provided they meet specific conditions. One key condition: the bulk drug substance used must either appear on the FDA's 503A Bulk Drug Substances list (often called the "bulks list"), be a component of an FDA-approved drug, or have a United States Pharmacopeia (USP) monograph [5].

AOD-9604 does not currently appear on the FDA's Category 1 (nominated and supported by clinical need) bulk drug substance list for 503A pharmacies. The FDA's published list of bulk drug substances under evaluation for 503A as of 2025 does not include AOD-9604 in a positively evaluated category [5]. This puts 503A pharmacies in a legally exposed position when compounding it.

503B Outsourcing Facilities

Section 503B covers registered outsourcing facilities that can compound drugs in larger quantities without patient-specific prescriptions. The FDA maintains a separate bulk drug substance list for 503B facilities. AOD-9604 is similarly absent from the FDA's current 503B Category 1 list [6]. Outsourcing facilities compounding AOD-9604 face comparable regulatory exposure to 503A pharmacies.

FDA Enforcement Discretion

The FDA does not prosecute every instance of unapproved compounding. The agency uses a risk-based enforcement-discretion model, prioritizing compounds that present safety risks, lack clinical rationale, or are being mass-produced without prescriptions. AOD-9604 has not been the subject of a published FDA warning letter specifically targeting Washington State providers as of this writing, but the absence of enforcement action is not the same as legal clearance [7].

The table below summarizes where AOD-9604 stands across the relevant federal lists. Providers and patients should review this alongside current FDA guidance before proceeding.

| Regulatory List | AOD-9604 Status (2025) | |---|---| | FDA-approved NDA/ANDA | Not approved | | 503A Category 1 bulk list | Not listed | | 503A Category 2 (do-not-compound) | Not listed | | 503B Category 1 bulk list | Not listed | | DEA Controlled Substances | Not scheduled | | USP monograph | No monograph exists |

Washington State Legal Framework

Washington State does not have a statute that independently legalizes or bans AOD-9604. The state's regulatory structure defers to federal law on unapproved drugs while adding its own pharmacy-practice and medical-practice rules on top.

Washington State Pharmacy Law

The Washington State Department of Health licenses pharmacies under RCW Chapter 18.64. The Pharmacy Quality Assurance Commission (PQAC) governs compounding practices through WAC 246-869. Washington pharmacies that compound AOD-9604 must comply with USP General Chapter 795 (non-sterile preparations) or USP 797 (sterile preparations, because most peptide formulations are injectable), and they operate under the same federal 503A conditions described above [8].

Washington Medical Practice Act

Licensed physicians, naturopathic physicians, and advanced practice registered nurses (APRNs) in Washington may prescribe compounded preparations for individual patients when a clinical need exists that cannot be met by an FDA-approved product. The medical practice act (RCW Chapter 18.71) does not enumerate specific peptides; it instead grants and can revoke prescribing authority based on standard-of-care principles. A Washington provider who prescribes AOD-9604 without documented clinical rationale may face board review, even if no criminal charge results.

No State-Level Scheduling

Washington's Uniform Controlled Substances Act (RCW Chapter 69.50) schedules substances under state law. AOD-9604 does not appear in Washington's schedule I through V lists. This means prescribing, dispensing, and possessing it is not a state criminal act in the way that, say, possessing unscheduled fentanyl analogs can be under specific circumstances [9].

How to Get AOD-9604 in Washington: The Legitimate Path

The only legally defensible path to AOD-9604 in Washington runs through a licensed prescriber and a compounding pharmacy that operates within USP 797 standards. The process looks like this in practice.

Step 1: Clinical Evaluation

A Washington-licensed physician, ARNP, or naturopathic physician conducts a full history, physical examination, and labs. For weight management, this typically includes fasting metabolic panel, lipid panel, and body composition assessment. The 2023 American Association of Clinical Endocrinology (AACE) Obesity Clinical Practice Guidelines recommend a comprehensive evaluation before initiating any weight-loss pharmacotherapy [10]. AOD-9604 is not among the AACE-recommended agents, which makes documented clinical rationale especially important.

Step 2: Prescription Issuance

The prescriber writes a patient-specific prescription for a compounded preparation of AOD-9604. In Washington, this prescription must include the patient's name, the compound's name and strength, dosage form, route, quantity, and the prescriber's DEA number if applicable (though AOD-9604 does not require DEA scheduling).

Step 3: Compounding Pharmacy Dispensing

A Washington-licensed compounding pharmacy, or an out-of-state pharmacy licensed to dispense into Washington, prepares the compound. Injectable AOD-9604 (the most common clinical form) must be prepared under USP 797 sterile-compounding conditions [8]. The pharmacy bears legal exposure for compounding an off-bulks-list substance; patients should confirm the pharmacy's inspection history and any relevant FDA Form 483 observations before filling.

Step 4: Administration and Monitoring

Most clinical protocols use subcutaneous injection of AOD-9604 at doses between 250 mcg and 500 mcg per day, typically administered in the morning on an empty stomach, based on dosing patterns from the Phase 2 trial data [2]. No FDA-approved dosing guideline exists. Monitoring for injection-site reactions, lipid changes, and any unexpected systemic effects is standard practice.

Safety Profile: What the Evidence Actually Shows

Phase 2 Trial Safety Data

The Phase 2 trials conducted by Metabolic Pharmaceuticals reported that AOD-9604 at oral doses up to 1 mg/day over 12 weeks did not produce significant changes in fasting glucose, insulin, or IGF-1 levels compared with placebo [2]. Adverse events were mild and included headache and nausea. No serious adverse events attributable to the compound were reported in these trials.

Subcutaneous Injection Risks

The Phase 2 data used oral administration. Most current clinical use involves subcutaneous injection, for which no published RCT safety data exists. Injection-site erythema, bruising, and lipodystrophy are general risks associated with any subcutaneous peptide injection, as documented in the broader peptide-therapy literature [11].

IGF-1 and Growth Axis

Because AOD-9604 is a fragment of hGH, providers often check baseline IGF-1 and monitor it during treatment. The Endocrine Society's clinical practice guideline on growth hormone deficiency notes that IGF-1 elevation carries risks of soft-tissue swelling and glucose intolerance [12]. The available AOD-9604 data suggest IGF-1 remains stable, but long-term injectable data are absent.

Comparison with FDA-Approved Weight-Loss Agents

Washington patients and providers should weigh AOD-9604's unproven regulatory status against available approved alternatives.

| Agent | FDA Approval | Mechanism | Mean Weight Loss (Trial) | |---|---|---|---| | Semaglutide 2.4 mg (Wegovy) | Yes (2021) | GLP-1 agonist | 14.9% at 68 weeks (STEP-1, N=1,961) [13] | | Tirzepatide 15 mg (Zepbound) | Yes (2023) | GIP/GLP-1 dual agonist | 20.9% at 72 weeks (SURMOUNT-1, N=2,539) [14] | | Orlistat 120 mg (Xenical) | Yes (1999) | Pancreatic lipase inhibitor | 8.9% at 52 weeks vs 5.8% placebo [15] | | AOD-9604 1 mg oral | No | Beta-3 adrenergic / lipolytic | Modest; Phase 2 only; no Phase 3 [2] |

The evidence gap between AOD-9604 and approved agents is substantial. Providers recommending AOD-9604 over an approved GLP-1 agonist should document the specific clinical reason, for example, GLP-1 intolerance or contraindication.

Telehealth and Online Prescribing in Washington

Washington State allows telehealth prescribing for compounded medications under WAC 246-919-605, provided the prescriber establishes a valid patient-provider relationship, which requires at minimum a synchronous audio-video consultation. A text-only or questionnaire-only encounter does not meet Washington's standard for establishing a valid prescribing relationship for a new patient [16].

Telehealth platforms operating across state lines must ensure the prescribing provider holds an active Washington medical license. The Washington Medical Commission (WMC) enforces this requirement and has disciplined out-of-state providers for prescribing without a Washington license.

Patients purchasing AOD-9604 from overseas websites or domestic research-chemical vendors without a prescription are obtaining the compound outside any legal framework. The FDA classifies such purchases as importation of an unapproved drug, and U.S. Customs may seize shipments [7].

Provider Risk Considerations

Washington prescribers who offer AOD-9604 face a layered risk profile.

Washington Medical Commission Standards

The WMC can initiate investigation if a prescriber's AOD-9604 use is alleged to fall below the standard of care. Because no clinical guideline from the Endocrine Society, AACE, or the American Medical Association currently endorses AOD-9604 for weight management, a prescriber defending off-label use must rely on documented informed consent, individualized clinical rationale, and monitoring protocols.

Malpractice Exposure

Washington follows the "reasonably prudent practitioner" standard in malpractice cases. Prescribing a compound with Phase 2-only evidence for a condition where Phase 3-proven agents exist creates a documentable deviation from established care. Malpractice insurers may exclude coverage for compounded peptide prescriptions; providers should verify their policy language before prescribing.

Documentation Best Practices

"The medical record should clearly reflect the clinical justification for the compounded preparation, including why commercially available alternatives are inadequate for this patient," states the PQAC guidance on compounding prescriptions [8]. A documented allergy to GLP-1 agonist excipients, a history of pancreatitis precluding GLP-1 use, or a specific patient preference supported by informed consent are examples of defensible rationale.